Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 409

1.

New pharmacotherapeutic approaches to obsessive-compulsive disorder.

Figee M, Denys D.

CNS Spectr. 2009 Feb;14(2 Suppl 3):13-23.

PMID:
19238126
2.

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.

Stein DJ, Montgomery SA, Kasper S, Tanghoj P.

Int Clin Psychopharmacol. 2001 Nov;16(6):357-61.

PMID:
11712625
3.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
4.

Escitalopram in the treatment of obsessive-compulsive disorder.

Zohar J.

Expert Rev Neurother. 2008 Mar;8(3):339-49. doi: 10.1586/14737175.8.3.339. Review.

PMID:
18345966
5.

Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.

Vythilingum B, Cartwright C, Hollander E.

Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S7-13. Review.

PMID:
11110014
6.

Beyond depression: citalopram for obsessive-compulsive disorder.

Pato MT.

Int Clin Psychopharmacol. 1999 May;14 Suppl 2:S19-26. Review.

PMID:
10471169
7.

Pharmacotherapy for obsessive-compulsive disorder.

Dougherty DD, Rauch SL, Jenike MA.

J Clin Psychol. 2004 Nov;60(11):1195-202.

PMID:
15389617
8.

The pathogenesis and treatment of obsessive-compulsive disorder.

Dolberg OT, Iancu I, Sasson Y, Zohar J.

Clin Neuropharmacol. 1996 Apr;19(2):129-47. Review.

PMID:
8777767
9.

Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.

Galvão-de Almeida A, Quarantini LC, Góis CR, Santos-Jesus R, Miranda-Scippa AM, de Oliveira IR, da Silva Prado H, Leckman JF, Rosário MC.

CNS Spectr. 2007 Jul;12(7):519-24.

PMID:
17603402
10.

Clinical predictors of drug nonresponse in obsessive-compulsive disorder.

Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S.

J Clin Psychiatry. 2005 Dec;66(12):1517-23.

PMID:
16401151
11.

Pharmacotherapy for obsessive-compulsive disorder.

Greist JH, Jefferson JW.

Br J Psychiatry Suppl. 1998;(35):64-70. Review.

PMID:
9829028
12.

New developments in the treatment of obsessive-compulsive disorder.

Leonard HL.

J Clin Psychiatry. 1997;58 Suppl 14:39-45; discussion 46-7. Review.

PMID:
9418745
13.

Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.

Denys D.

Psychiatr Clin North Am. 2006 Jun;29(2):553-84, xi. Review.

PMID:
16650723
14.

The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.

Denys D, Zohar J, Westenberg HG.

J Clin Psychiatry. 2004;65 Suppl 14:11-7.

15.

Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.

Stein DJ, Andersen EW, Overo KF.

Rev Bras Psiquiatr. 2007 Dec;29(4):303-7.

16.

The medical treatment of obsessive-compulsive disorder and anxiety.

Bandelow B.

CNS Spectr. 2008 Sep;13(9 Suppl 14):37-46. Review.

PMID:
18849910
17.

Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.

Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell'osso M.

CNS Spectr. 2008 Nov;13(11):971-6.

PMID:
19037176
18.

Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.

Lydiard RB.

Int Clin Psychopharmacol. 1994 Jun;9 Suppl 3:33-7. Review.

PMID:
7963449
19.
20.

OCD: where the serotonin selectivity story begins.

Pigott TA.

J Clin Psychiatry. 1996;57 Suppl 6:11-20. Review.

PMID:
8647793

Supplemental Content

Support Center